USANA Health Sciences (NYSE:USNA) Upgraded at Zacks Research

Zacks Research upgraded shares of USANA Health Sciences (NYSE:USNA) from a hold rating to a strong-buy rating in a research report report published on Monday,Zacks.com reports.

A number of other brokerages have also issued reports on USNA. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Friday, March 27th. Wall Street Zen raised USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

USANA Health Sciences Price Performance

USNA opened at $18.79 on Monday. The firm has a market cap of $346.81 million, a P/E ratio of 34.16, a PEG ratio of 0.77 and a beta of 0.71. USANA Health Sciences has a 1-year low of $16.60 and a 1-year high of $38.32. The company has a 50 day simple moving average of $18.87 and a two-hundred day simple moving average of $20.22.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, February 17th. The company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.41 by $0.19. USANA Health Sciences had a net margin of 1.16% and a return on equity of 6.75%. The firm had revenue of $226.20 million for the quarter, compared to the consensus estimate of $225.96 million. Equities analysts anticipate that USANA Health Sciences will post 2.45 earnings per share for the current year.

Insider Activity

In other news, insider Joshua Foukas sold 4,461 shares of the stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $21.34, for a total transaction of $95,197.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.63% of the stock is owned by company insiders.

Institutional Investors Weigh In On USANA Health Sciences

A number of hedge funds have recently bought and sold shares of the business. National Bank of Canada FI grew its stake in shares of USANA Health Sciences by 166.6% in the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after buying an additional 1,201 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of USANA Health Sciences by 382.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after buying an additional 1,901 shares in the last quarter. Parallel Advisors LLC raised its position in shares of USANA Health Sciences by 1,354.3% during the 4th quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock valued at $76,000 after buying an additional 3,589 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of USANA Health Sciences by 52.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock valued at $106,000 after acquiring an additional 1,327 shares during the last quarter. Finally, iSAM Funds UK Ltd bought a new position in shares of USANA Health Sciences in the 3rd quarter valued at about $120,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.